Eli Lilly

#Alchemab Therapeutics #Amyotrophic lateral sclerosis (ALS) #Collaboration #Eli Lilly

Lilly and Alchemab collaborate on novel therapies for ALS 

Eli Lilly and Alchemab Therapeutics hope to discover novel therapeutic candidates to treat amyotrophic lateral sclerosis (ALS) as part of a new research collaboration.  Alchemab’s technology platform uses patient samples from individuals with unusually slow rates of disease progression to identify antibodies associated with resilience.   The company believes these antibodies,… Read More

#Business & Investment #News

Scales showing a comparison between Mounjaro and Ozempic
#Eli Lilly #GLP-1 #Obesity #Phase III trial #Weight loss

New data show Zepbound/Mounjaro superior to Wegovy for weight loss

Eli Lilly’s Zepbound/Mounjaro (tirzepatide) provided a 47% greater relative weight loss compared to Wegovy (semaglutide, also known as Ozempic), according to topline results from the SURMOUNT-5 Phase IIIb clinical trial.  On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy. … Read More

#News #Trending News

Dementia
#Alzheimer's #Drug development #Eli Lilly #Monoclonal antibodies #National Institute for Health and Care Excellence (NICE) #Regulatory

UK’s NICE rejects second disease-modifying therapy for Alzheimer’s 

UK regulator the National Institute for Health and Care Excellence (NICE) has ruled against the use of a second monoclonal antibody for Alzheimer’s disease, just two months after rejecting Eisai’s lecanemab (Leqembi).  NICE concluded that Eli Lilly’s donanemab (Kisunla) only provides a “small benefit”… Read More

#News

Research in genetics laboratory
#Collaboration #Eli Lilly #Genetics / genomics #HAYA Therapeutics #Obesity

Lilly and HAYA collaborate to find genome targets for obesity

Eli Lilly and biotechnology company HAYA Therapeutics have announced a multi-year agreement to apply HAYA’s RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. The partners aim to identify multiple regulatory genome derived RNA-based drug targets to address these chronic conditions. Under the… Read More

#Business & Investment #News

Woman tests blood glucose level
#Diabetes #Eli Lilly #GLP-1 #Obesity #Phase III trial #Weight loss

Weight loss drug reduced type 2 diabetes risk by 94%

Topline results from the SURMOUNT-1 three-year study have shown that tirzepatide (Zepbound and Mounjaro) significantly reduced the risk of progression to type 2 diabetes by 94% among adults with pre-diabetes and obesity or overweight. Additionally, treatment with tirzepatide resulted in sustained weight loss through the treatment… Read More

#News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Eli Lilly #FDA #Neurodegenerative disorders #Phase III trial

FDA approves second anti-amyloid beta antibody for Alzheimer’s

Eli Lilly’s anti-amyloid beta monoclonal antibody (mAb) Kisunla (donanemab) has become the second disease-modifying therapy for Alzheimer’s disease (AD) to reach the US market, following approval by the US Food and Drug Administration (FDA). It has been approved by the regulator for the treatment of patients with mild cognitive impairment… Read More

#News #Regulatory #Trending News

Man wearing a cap mask while sleeping
#American Diabetes Association #Diabetes #Eli Lilly #GLP-1 #Phase III trial #Sleep apnoea #Weight loss

Weight loss drug reduces sleep apnoea severity by 62%

Tirzepatide demonstrated a mean reduction of up to 62.8% on the apnoea-hypopnea index (AHI) compared to placebo in the SURMOUNT-OSA Phase III clinical trials. The drug was tested for the treatment of moderate-to-severe obstructive sleep apnoea (OSA) in adults with obesity, with and without positive airway… Read More

#News #Trending News

Dementia
#Alzheimer's #Eli Lilly #FDA #Neurodegenerative disorders #Phase III trial

FDA advisory committee meeting delays approval of donanemab

The US Food and Drug Administration (FDA) has revealed plans to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) to discuss the Phase III TRAILBLAZER-ALZ 2 trial. The trial evaluated the efficacy and safety of Eli Lilly’s donanemab in early symptomatic Alzheimer's disease. The… Read More

#News #Regulatory

Stock market
#Diabetes #Eli Lilly #GlobalData #Market reporting #Novo Nordisk #Vertex #Weight loss

Lilly, Novo Nordisk and Vertex lead on market capitalisation growth

The top 20 global biopharmaceutical companies have reported 1.6% market capitalisation growth to $3.67 trillion in 2023, according to data analysts GlobalData. The top 20 global biopharmaceutical companies experienced varied year-on-year (YoY) market capitalisation shifts in 2023 amid the macroeconomic headwinds, steep patent cliffs and the commencement of US drug… Read More

#Business & Investment #News

Child with hearing aids
#Akouos #Eli Lilly #Gene mutation #Gene therapy #Hearing Loss #Phase II trial

Gene therapy cures genetic hearing loss

In the first case of its kind, gene therapy has restored hearing in a patient in the United States. Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 Phase I/II study participant. AK-OTOF is a gene… Read More

#News #Trending News

Acute lymphoblastic leukemia
#Blood cancer #Eli Lilly #FDA #Leukaemia #Oncology

FDA approves second indication for Lilly’s BTK inhibitor Jaypirca

Eli Lilly’s Jaypirca (pirtobrutinib) has been approved in the US for lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL). It has been granted approval by the Food and Drug Administration (FDA) to treat patients who have received at least two lines of therapy, including a Bruton's tyrosine kinase (BTK) inhibitor and… Read More

#News #Regulatory

#Eli Lilly #FDA #MHRA #Obesity #Regulatory #Weight loss

Tirzepatide approved for weight management in US and UK

The US Food and Drug Administration has approved Zepbound (tirzepatide) injection for chronic weight management alongside a reduced calorie diet and increased physical activity. It is approved in adults with obesity (body mass index of 30 kilograms per square meter (kg/m2) or greater) or overweight (body mass index of 27kg/m2… Read More

#News #Regulatory #Trending News

International Space Station (ISS)
#Drug development #Drug discovery #Eli Lilly #Lab space #Pharmaceuticals #Redwire

First spaceflight mission for drug development lab

Redwire will launch its in-space pharmaceutical manufacturing platform, PIL-BOX, onboard SpaceX’s 29th cargo resupply services mission (SpaceX-29) for NASA to the International Space Station (ISS). The platform is designed to offer pharmaceutical companies and researchers novel and flexible services to grow small-batch crystals of protein-based pharmaceuticals… Read More

#Editor's Choice #News

Alzheimer's disease
#Alzheimer's #Clinical trials #Eli Lilly #Neuroscience

Donanemab significantly slowed decline in early Alzheimer’s disease trial 

Eli Lilly has announced positive results of the TRAILBLAZER-ALZ 2 Phase III study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease.   Donanemab met the primary endpoint of change from baseline until 18 months on the integrated Alzheimer’s Disease… Read More

#News #Trending News

Crohn's disease
#Eli Lilly #Gastroenterology #MHRA #Phase III trial #Regulatory

Eli Lilly’s ulcerative colitis drug approved in Great Britain

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to Eli Lilly’s mirikizumab for moderately to severely active ulcerative colitis. The drug is approved in adult patients who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a… Read More

#News #Regulatory

#Artificial intelligence (AI) #Automation / robotics #Collaboration #Eli Lilly #Partnership #XtalPi

Eli Lilly and XtalPi sign AI drug discovery collaboration

Eli Lilly and XtalPi have entered an AI drug discovery collaboration of up to $250 million in upfront and milestone payments. XtalPi is a pharmaceutical technology company with operations in China and the US. The collaboration will use XtalPi’s integrated AI and robotics platform… Read More

#News